FDA Warns on Rare Serious Liver Injury With Hep C Medicines

Aug. 28, 2019, 6:20 PM UTC

Drugs that treat hepatitis C, whose high prices have previously sparked outrage, can in rare instances cause liver failure and other complications, the U.S. Food and Drug Administration said.

The FDA said it had received reports that drugs made by Gilead Sciences Inc., AbbVie Inc. and Merck & Co. can in some cases lead to worsening liver function in patients who already had moderate or severe liver damage, according to a statement Aug. 28. The agency said the drugs remain safe for patients with mild liver disease.

Shares in all three companies were little changed following the news. Requests for ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.